Page 41 - Quest Diagnostics News Today

Quest Diagnostics (DGX), while reporting weak profit in its first quarter despite higher revenues, on Tuesday raised its fiscal 2024 forecast. In pre-market activity on the NYSE, Quest shares were gaining around 3 percent to trade at $134.

World markets have cheered up a bit this week, but ailing Tesla's tanking stock price faces a critical earnings test later on Tuesday and this month's European business pulse proved surprisingly racy. Relief at cooling Middle East tensions helped steady the ship on Monday after the worst week on Wall Street since 2022 - with bellwether chip giant Nvidia recouping some of Friday's 10% lunge as Big Tech megacaps get set to report first quarter updates over three days of a heavy ear...

Comprehensive Analysis of Quest Diagnostics' Latest Financial Performance

Q1 2024 CONFERENCE CALL SCRIPT TUE, APR 23, 2024, 8:30 am ET 888-455-0391 PASSCODE: 7895081 Conference operator:...

(Reuters) - Laboratory operator Quest Diagnostics raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests. Demand for routine diagnostic health checkups has grown over t...

Quest Diagnostics (NYSE: ) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to…

Quest Diagnostics (NYSE:DGX – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 8.720-8.970 for the period, compared to the consensus EPS estimate of 8.750. The company issued revenue guidance of $9.4 billion-$9.5 billion, compared to the consensus revenue estimate of $9.4 billion. […]

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

The at-home testing industry, from Covid to cancer, may be worth over $2 billion by 2025 : Rashtra News #athome #testing #industry #Covid #cancer #worth #billion The at-home testing market is bigger than just Covid tests, and it's bigger than over-the-counter pregnancy tests.In fact, the emerging marketplace of consumer-initiated lab testing may be worth more

Companys AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health SECAUCUS,...